Kancera Investor Relations Material

Kancera AB is a Swedish biotechnology company focusing on developing pharmaceuticals for the treatment of severe diseases, particularly cancer and inflammatory conditions. The company's efforts are primarily directed towards creating small molecule drug candidates that target disease-promoting immune and cancer cells, specifically utilizing the fractalkine axis. Kancera's work is divided into two main areas: Pharmaceutical Development and Industrial Research and Development (R&D). Solna, Stockholm, Sweden, and its shares are listed on the Stockholm Stock Exchange.